Do you have an idea for a new product or new service?Win NOK 250,000!
The deadline for submitting entries has expired. Idéprisen 2023 will be announced in 2023.
INVEN2 WANTS YOUR IDEAS FOR THE 2022 IDÉPRISEN AWARD.
Maybe you and your researcher colleagues will win the first prize of NOK 250,000, in addition to getting advice and help with bringing your idea to the market?
Two other ideas will be awarded NOK 25,000 each. The money must be spent on further developing the idea.
The ideas are selected by a jury comprising representatives of Inven2’s innovation team.
ABOUT THE IDÉPRISEN AWARD
The Idéprisen award is an annual initiative by Inven2 to generate more ideas from skilled researchers and to reward the most innovative ideas. Inven2 wants to get more research out to the public by developing products and services that benefit society.
Are you employed by the University of Oslo or the South-Eastern Norway Regional Health Authority and have a good idea for an innovative product or service? Submit your idea for Idéprisen and win NOK 250,000, and get advice and help to bring your idea to the market.
1. 1st prize: NOK 250,000
2nd prize: NOK 25,000
2nd prize: NOK 25,000
The award money must be spent on further developing the idea.
The competition is open to employees of the University of Oslo or the South-Eastern Norway Regional Health Authority. The idea must be based on research carried out at these institutions.
The deadline for submitting ideas is 11 May 2022. mai 2022.
All ideas will be treated confidentially.
The winners will be announced at Inven2’s Innovasjonsdag event on 2 June. juni!
The winners will be announced at Inven2’s Innovasjonsdag event on 2 June and on Inven2’s website the next day. juni og på Inven2s nettside neste dag.
Who is Inven2?
Inven2 administers the intellectual property rights of the University of Oslo and the South-Eastern Norway Regional Health Authority. We work together with companies in over 20 countries to bring technology to the market. In 2021, we received 131 new ideas, established 8 research-based companies and signed 15 new licencing agreements.
‘We won Inven2’s Idéprisen award in 2014 for our work on combining natural killer cells, NK cells, with T cell receptors, TCRs. It was great to receive this recognition.’
Today, this research is licensed to Zelluna Immunotherapy AS, which develops ground-breaking immunotherapy against cancer.
PREVIOUS PRIZE WINNERS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
IDÉPRISEN WINNERS 2011–2021
«A novel method to produce soluble T-vell reseptorer»
Johanna Olweus, Sebastien Wälcli, Gunnar Kvalheim, Gustav Gaudernack, OUS
Dr. Kenneth Bihlet, AHUS
«A novel Technology for Development of prophylactic or Therapeutics vaccines against diseases such as HIV and cancer»
Aram Andersen, Bjarne Bogen, Inger Øynebråten, UiO/OUS
«A universal killer-T cell for personalized medicine »
Else Marit, Sebastien Wälcli, Gunnar Kvalheim, Gustav Gaudernack, OUS
“Improved 3D visualization for web sites”
Fredrik Arnfinsen, Bjarte Aarseth, UiO
“Ny strålekilde for kreftbehandling”
«Ny behandling av hjerterytmeforstyrrelser»
Jonas Skogestad og Magnus Aronsen, UiO/OUS
Ijlal Loutfi, UiO
“Smartsokk for diabetikere”
Christian Tronstad, Jonny Hisdal, Trond Jenssen, Inge Petter Kleggetveit, Ørjan G. Martinsen, Håvard Kalvøy og Ole Elvebakk. UiO/OUS/AHUS
“Kirurgiske hjelmer som er smittesikre for koronaviruset”
Max Temmesfeld, Håvard Hoelsæter og Mikael Omlid. AHUS
“AI for avansert fosterdiagnostikk”
Kjell-Inge Gjesdal, Carl Petter Skaar, Vigdis Hellestad, Anne Enlid. OUS/UiO/NordicCAD/AHUS
We’re here to answer any questions you may have.
DESCRIPTION OF IDEA
Use this form to describe your idea for Inven2’s idea competition. The first prize is NOK 250,000 for further development of the idea. Emphasis will be placed on the possibilities of achieving a commercial product or service. For us to be able to understand and assess your idea, you must fill in the boxes below in accordance with the prompts. All ideas will be treated in strict confidence